Related Companies
|
[]
|
||||||||
Related Funds
|
[]
|
||||||||
English
|
|||||||||
oda_NewBusinessRelationAbstract|
|
|
||||||||
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_AnnouncementContentSection|
|
|
||||||||
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
|
|
Müşteri (Customer)
|
|||||||
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
|
|
Onko İlaç Sanayi ve Ticaret A.Ş.
|
|||||||
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
|
|
-
|
|||||||
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
|
|
-
|
|||||||
oda_ExpectedStartingDateOfNewBusinessRelation|
|
|
01/01/2022
|
|||||||
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
|
|
Detailed Below
|
|||||||
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
|
|
It will have positive impact.
|
|||||||
oda_ExplanationSection|
|
|
||||||||
oda_ExplanationTextBlock|
|
-Unofficial Translation- An agreement between our Company Gen İlaç ve Sağlık Ürünleri A.Ş. ("Gen") and Onko İlaç Sanayi ve Ticaret A.Ş. ("Onko İlaç") has been signed on 15.02.2021, about sale of a medicine named "Genivig" which used for treatment of neurological haematological diseases and imported by our Company to the pharmacies all over Turkey through Onko İlaç. Sales and distribution rights granted to Onko İlaç with the agreement do not cover tender sales and sale to private hospitals, only covers sales and distribution to pharmacies. In the Agreement, it is set forth that the amount of medicine to be supplied to Onko İlaç in 2022 will be determined separately. In order to determine amount of medicine that will be suppied to Onko İlaç in 2022, an additional agreement ("Additional Agreement") has been signed between our Company and Onko İlaç on 18.11.2021. According to the Additional Agreement, it is decided that 50.000 boxes medicine will be sold to Onko İlaç in 2022. When the total product price to be sold to Onko İlaç according to the Additional Agreement is calculated over the current TİTCK(Turkish Medicine and Medical Devices Agency) sales price, it corresponds to a gross TL 225.000.000. With the Additional Agreement, our company's national distribution network for the medicine named "Genivig" will expand, and at the same time, the access of patients using this medicine will be facilitated. |
We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.